keyword
MENU ▼
Read by QxMD icon Read
search

Pet psma

keyword
https://www.readbyqxmd.com/read/29232245/intense-68ga-psma-uptake-in-diverticulum-of-the-sigmoid-colon
#1
Mads Ryø Jochumsen, Kirsten Bouchelouche
We present a case of a diverticulum of the sigmoid colon with intense prostate-specific membrane antigen (PSMA) activity on Ga-PSMA PET/CT. CT scan and colonoscopy showed no signs of inflammation or malignancy. This case presents an addition to the collection of benign pitfalls when reporting PSMA PET/CT; however, a Ga-PSMA up-taking focus in the colon should always cause further examination, as malignant etiology must be ruled out.
December 11, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29230009/the-use-of-pet-ct-in-prostate-cancer
#2
REVIEW
Roger Li, Gregory C Ravizzini, Michael A Gorin, Tobias Maurer, Matthias Eiber, Matthew R Cooperberg, Mehrdad Alemozzaffar, Matthew K Tollefson, Scott E Delacroix, Brian F Chapin
BACKGROUND: Positron emission tomography/computed tomography (PET/CT) has recently emerged as a promising diagnostic imaging platform for prostate cancer. Several radiolabelled tracers have demonstrated efficacy for cancer detection in various clinical settings. In this review, we aim to illustrate the diverse use of PET/CT with different tracers for the detection of prostate cancer. METHODS: We searched MEDLINE using the terms 'prostate cancer', 'PET', 'PET/CT' and 'PET/MR')...
December 11, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/29191856/psma-11-derived-dual-labeled-psma-inhibitors-for-preoperative-pet-imaging-and-precise-fluorescence-guided-surgery-of-prostate-cancer
#3
Ann-Christin Baranski, Martin Schäfer, Ulrike Bauder-Wüst, Mareike Roscher, Jana Schmidt, Esther Stenau, Tobias Simpfendörfer, Dogu Teber, Lena Maier-Hein, Boris Hadaschik, Uwe Haberkorn, Matthias Eder, Klaus Kopka
Resection of tumor lesions using targeted dual-modality probes combining preoperative imaging with intraoperative guidance is of high clinical relevance and might considerably impact the outcome of prostate cancer therapy. This work aims at the development of dual-labeled prostate specific membrane antigen (PSMA)-inhibitors derived from the established positron emission tomography (PET)- and N,N'-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid (HBED-CC) based tracer 68Ga-Glu-urea-Lys(Ahx)-HBED-CC (68Ga-PSMA-11) to allow accurate intraoperative detection of PSMA-positive tumor lesions...
November 30, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29188198/evaluation-of-the-changing-landscape-of-prostate-cancer-diagnosis-and-management-from-2005-to-2016
#4
Kirsten R Carlaw, Henry H Woo
Background: Approaches to prostate cancer (PCa) diagnosis and treatment have evolved significantly over past decades. There has been an increasing focus on minimizing overdiagnosis and overtreatment of clinically insignificant PCa. The objective of this study was to evaluate the changes in the diagnostic approach and initial treatment strategy that has evolved over time in an Australian urological private practice. Materials and methods: Men with newly diagnosed PCa were identified from the private practice electronic and paper medical records from 2005 to 2016 and data was consolidated into six groups of 2-year intervals...
December 2017: Prostate International
https://www.readbyqxmd.com/read/29188197/68ga-prostate-specific-membrane-antigen-positron-emission-tomography-computed-tomography-in-advanced-prostate-cancer-current-state-and-future-trends
#5
REVIEW
Cristian Udovicich, Marlon Perera, Michael S Hofman, Shankar Siva, Andres Del Rio, Declan G Murphy, Nathan Lawrentschuk
The early and accurate detection of prostate cancer is important to ensure timely management and appropriate individualized treatment. Currently, conventional imaging has limitations particularly in the early detection of metastases and at prostate-specific antigen (PSA) levels < 2.0 ng/mL. Furthermore, disease management such as salvage radiotherapy is best at low PSA levels. Thus, it is critical to capture the disease in the oligometastatic stage as disease progression and commencement of systemic therapies can be delayed by metastasis-directed therapy...
December 2017: Prostate International
https://www.readbyqxmd.com/read/29185010/preliminary-results-on-response-assessment-using-68ga-hbed-cc-psma-pet-ct-in-patients-with-metastatic-prostate-cancer-undergoing-docetaxel-chemotherapy
#6
Anna Katharina Seitz, Isabel Rauscher, Bernhard Haller, Markus Krönke, Sophia Luther, Matthias M Heck, Thomas Horn, Jürgen E Gschwend, Markus Schwaiger, Matthias Eiber, Tobias Maurer
PURPOSE: To investigate the value of 68Ga-HBED-CC PSMA (68Ga-PSMA) PET/CT for response assessment in metastatic castration-sensitive and castration-resistant prostate cancer (mCSPC and mCRPC) during docetaxel chemotherapy. METHODS: 68Ga-PSMA PET/CT was performed in seven mCSPC patients before and after six cycles of upfront docetaxel chemotherapy and in 16 mCRPC patients before and after three cycles of palliative docetaxel chemotherapy. Radiographic treatment response was evaluated separately on the 68Ga-PSMA PET and CT datasets...
November 28, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29181556/oligometastases-in-prostate-cancer-metabolic-response-in-follow-up-psma-pet-cts-after-hypofractionated-igrt
#7
René Baumann, Mark Koncz, Ulf Luetzen, Fabian Krause, Juergen Dunst
BACKGROUND: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMAPET/CT) is a new and evolving diagnostic method in prostate cancer with special impact on treatment planning in image-guided radiotherapy (IGRT). Initial results of metabolic response in repeated PSMA PET/CTs after hypofractionated IGRT for metastatic lesions are reported here. MATERIALS AND METHODS: Of 280 patients investigated with 68Ga-PSMA PET/CT in the period from 01/2014 through 12/2016 in the authors' department, patients were selected according to the following criteria: oligometastatic disease at initial PSMA PET/CT defined as not more than five metastatic lesions, hypofractionated IGRT to all lesions, no systemic therapy in the last 6 months and during follow-up, and at least one follow-up PSMA PET after radiotherapy...
November 27, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29166327/68ga-prostate-specific-membrane-antigen-uptake-in-gastrointestinal-stromal-tumor
#8
Tom Laurens, Fred Witjes, Marcel Janssen, Uta Flucke, Martin Gottardt
A 62-year-old man with recently diagnosed prostatic adenocarcinoma was referred for a whole-body Ga-prostate-specific membrane antigen (PSMA) PET/CT scan for staging. Although the scan did not reveal metastatic disease, it did reveal a PSMA-avid lesion in the upper abdomen located between the liver and the stomach. Histopathologic examination demonstrated a gastrointestinal stromal tumor. The lesion demonstrated increased uptake in the margins of the tumor with a central photopenic area, which we consider to be the typical pattern on PSMA images of a gastrointestinal stromal tumor, based on theoretical PSMA distribution in such a tumor and other reported cases...
January 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29158832/clinical-translation-and-first-in-human-use-of-44-sc-sc-psma-617-for-pet-imaging-of-metastasized-castrate-resistant-prostate-cancer
#9
Elisabeth Eppard, Ana de la Fuente, Martina Benešová, Ambreen Khawar, Ralph A Bundschuh, Florian C Gärtner, Barbara Kreppel, Klaus Kopka, Markus Essler, Frank Rösch
BACKGROUND: Various trivalent radiometals are well suited for labeling of DOTA-conjugated variants of Glu-ureido-based prostate-specific membrane antigen (PSMA) inhibitors. The DOTA-conjugate PSMA-617 has proven high potential in PSMA radioligand therapy (PSMA-RLT) of prostate cancer as well as PET imaging when labeled with lutetium-177 and gallium-68 respectively. Considering the relatively short physical half-life of gallium-68 this positron emitter precludes prolonged acquisition periods, as required for pre-therapeutic dosimetry or intraoperative applications...
2017: Theranostics
https://www.readbyqxmd.com/read/29144944/re-impact-of-ga-68-psma-11-pet-on-management-in-patients-with-biochemically-recurrent-prostate-cancer
#10
Samir S Taneja
No abstract text is available yet for this article.
December 2017: Journal of Urology
https://www.readbyqxmd.com/read/29137414/salvage-lymph-node-dissection-after-68-ga-psma-or-18-f-fec-pet-ct-for-nodal-recurrence-in-prostate-cancer-patients
#11
Annika Herlemann, Alexander Kretschmer, Alexander Buchner, Alexander Karl, Stefan Tritschler, Lina El-Malazi, Wolfgang P Fendler, Vera Wenter, Harun Ilhan, Peter Bartenstein, Christian G Stief, Christian Gratzke
The management of patients with biochemical recurrence (BCR) after definitive treatment for prostate cancer remains controversial. Our aim was to determine survival rates and complications of salvage lymph node dissection (sLND) in patients with recurrent prostate cancer after radical prostatectomy, while evaluating biochemical response (BR) with two different positron emission tomography/computed tomography (PET/CT) tracers used for preoperative imaging. sLND was performed in 104 patients diagnosed with isolated nodal recurrence on either (18)F-fluoroethylcholine ((18)F-FEC) or (68)Ga-PSMA-HBED-CC ((68)Ga-PSMA) PET/CT...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29134231/patterns-of-relapse-as-determined-by-68-ga-psma-ligand-pet-ct-after-radical-prostatectomy-importance-for-tailoring-and-individualizing-treatment
#12
Christoph Henkenberens, Thorsten Derlin, Frank M Bengel, Tobias L Ross, Hans-Jürgen Wester, Katja Hueper, Markus A Kuczyk, Hans Christiansen, Christoph A von Klot
PURPOSE: To evaluate the patterns of relapse and impact on the intended treatment when using (68)Ga-prostate-specific membrane antigen (PSMA) ligand positron emission tomography/computed tomography (PET/CT) imaging for restaging of disease in patients with biochemical relapse after radical prostatectomy (RP) before salvage radiotherapy (sRT). METHODS: In all, 39 patients with biochemical recurrence after RP who had no primary indication for adjuvant RT due to the absence of biologically unfavorable disease (e...
November 13, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29132714/psma-rads-version-1-0-a-step-towards-standardizing-the-interpretation-and-reporting-of-psma-targeted-pet-imaging-studies
#13
EDITORIAL
Steven P Rowe, Kenneth J Pienta, Martin G Pomper, Michael A Gorin
The use of [(18)F]- and [(68)Ga]-labeled inhibitors of prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of prostate cancer is now widespread. We have proposed a reporting and data system called PSMA-RADS version 1.0, which is a framework for classifying PSMA-targeted PET scans and individual findings into categories that reflect the likelihood of the presence of prostate cancer.
November 10, 2017: European Urology
https://www.readbyqxmd.com/read/29132644/delineating-sites-of-failure-following-post-prostatectomy-radiation-treatment-using-68-ga-psma-pet
#14
Keelan Byrne, Thomas Eade, Andrew Kneebone, Linxin Guo, Ed Hsiao, Geoff Schembri, Carolyn Kwong, Julia Hunter, Louise Emmett, George Hruby
PURPOSE: To identify sites of failure with (68)Ga-PSMA-PET (PSMA-PET) imaging in patients who have Biochemical Failure (BF) following post-prostatectomy radiotherapy. MATERIAL AND METHODS: Between June 2006 and January 2016, 409 men received post prostatectomy intensity modulated radiation treatment (IMRT) with protocolised planning. 310 patients received radiation treatment (RT) to the Prostate Fossa (PF) alone and 99 patients received RT to PF and pelvic lymphatics (PF + LN) usually in combination with androgen deprivation (AD) therapy...
November 10, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/29126446/detection-level-and-pattern-of-positive-lesions-using-psma-pet-ct-for-staging-prior-to-radiation-therapy
#15
Nina-Sophie Schmidt-Hegemann, Wolfgang Peter Fendler, Alexander Buchner, Christian Stief, Paul Rogowski, Maximilian Niyazi, Chukwuka Eze, Minglun Li, Peter Bartenstein, Claus Belka, Ute Ganswindt
BACKGROUND: To determine the potential role of 68Ga-PSMA positron emission tomography/computed tomography (PET/CT) in radiotherapy (RT) planning for prostate cancer (PCa). METHODS: One hundred twenty-nine patients (pts) with 68Ga-PSMA PET/CT were retrospectively analysed. Potentially influencing factors (androgen deprivation therapy, amount of 68Ga-PSMA-HBED-CC, PSA doubling time ≤/> 10 months, PSA before PET/CT, T-/N-category and Gleason score) were evaluated by logistic regression analysis...
November 10, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/29123013/-68-ga-psma-pet-ct-mapping-of-prostate-cancer-biochemical-recurrence-following-radical-prostatectomy-in-270-patients-with-psa-1-0ng-ml-impact-on-salvage-radiotherapy-planning
#16
Jérémie Calais, Johannes Czernin, Minsong Cao, Amar U Kishan, John V Hegde, Narek Shaverdian, Kiri A Sandler, Fang-I Chu, Chris R King, Michael L Steinberg, Isabel Rausher, Nina-Sophie Schmidt-Hegemann, Thorsten Poeppel, Philipp Hetkamp, Francesco Ceci, Ken Herrmann, Wolfgang P Fendler, Matthias Eiber, Nicholas G Nickols
Background: Target volume delineations for prostate cancer (PCa) salvage radiotherapy (SRT) after radical prostatectomy are usually drawn in the absence of visibly recurrent disease. Gallium-68 Prostate Specific Membrane Antigen Positron Emission Tomography/Computed Tomography ((68)Ga-PSMA-11 PET/CT) detects recurrent PCa with sensitivity superior to standard of care imaging at serum prostate specific antigen (PSA) values low enough to impact target volume delineations for routine SRT. OBJECTIVE: To i) map the recurrence pattern of PCa early biochemical recurrence (BCR) after radical prostatectomy with (68)Ga-PSMA-11 PET/CT in patients with serum PSA levels <1 ng/ml, ii) determine how often consensus clinical target volumes (CTV) based on the Radiation Therapy Oncology Group (RTOG) guidelines cover (68)Ga-PSMA-11 PET/CT-defined disease, and iii) assess the potential impact of (68)Ga-PSMA-11 PET/CT on SRT...
November 9, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29123012/prostate-cancer-molecular-imaging-standardized-evaluation-promise-proposed-mitnm-classification-for-the-interpretation-of-psma-ligand-pet-ct
#17
Matthias Eiber, Ken Herrmann, Jeremie Calais, Boris Hadaschihk, Frederik L Giesel, Markus Hartenbach, Thomas Hope, Robert Reiter, Tobias Maurer, Wolfgang A Weber, Wolfgang P Fendler
Prostate-specific membrane antigen (PSMA)-ligand positron emission tomography (PET)-imaging provides unprecedented accuracy for whole body staging of prostate cancer. As PSMA-ligand PET/computed tomography (CT) is increasingly adopted in clinical trials and routine practice worldwide, a unified language for image reporting is urgently needed. We propose a molecular imaging tumor, node and metastasis system (miTNM Version 1.0) as standardized reporting framework for PSMA-ligand PET/CT or PET/magnetic resonance imaging (MRI)...
November 9, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29115970/comparison-of-68ga-psma-11-pet-ct-with-mpmri-for-preoperative-lymph-node-staging-in-patients-with-intermediate-to-high-risk-prostate-cancer
#18
Qing Zhang, Shiming Zang, Chengwei Zhang, Yao Fu, Xiaoyu Lv, Qinglei Zhang, Yongming Deng, Chuan Zhang, Rui Luo, Xiaozhi Zhao, Wei Wang, Feng Wang, Hongqian Guo
BACKGROUND: To evaluate the diagnostic value of 68Ga-PSMA-11 PET-CT with multiparametric magnetic resonance imaging (mpMRI) for lymph node (LN) staging in patients with intermediate- to high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP) with pelvic lymph node dissection (PLND). METHODS: We retrospectively identified 42 consecutive patients with intermediate- to high-risk PCa according to D'Amico and without concomitant cancer. Preoperative 68Ga-PSMA-11 PET-CT, pelvic mpMRI and subsequent robot assisted laparoscopic RP with PLND were performed in all patients...
November 7, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/29107272/68gallium-prostate-specific-membrane-antigen-pet-computed-tomography-for-primary-and%C3%A2-secondary-staging-in-prostate-cancer
#19
REVIEW
Michael Chaloupka, Annika Herlemann, Melvin D'Anastasi, Clemens C Cyran, Harun Ilhan, Christian Gratzke, Christian G Stief
Prostate-specific membrane antigen (PSMA) PET has been recently introduced for the diagnosis of patients with metastatic prostate cancer (PCa). Until today, staging of patients with PCa relied mostly on morphologic features, such as size or shape, resulting in low detection rates in disease recurrence. PSMA PET imaging provides molecular information and, in combination with conventional imaging, offers improved sensitivity and specificity. This review discusses the benefits and limitations of PSMA imaging in the setting of primary staging and detection of recurrent disease in comparison with standard-of-care imaging techniques...
November 2017: Urologic Clinics of North America
https://www.readbyqxmd.com/read/29101444/-68-ga-psma-11-pet-ct-in-primary-staging-of-prostate-carcinoma-preliminary-results-on-differences-between-black-and-white-south-africans
#20
Mike Sathekge, Thabo Lengana, Alex Maes, Mariza Vorster, JanRijn Zeevaart, Ismaheel Lawal, Thomas Ebenhan, Christophe Van de Wiele
PURPOSE: The incidence of prostate cancer is 60% higher and the mortality rate is two- to three-times greater in black versus white men. We report on differences in (68)Ga-PSMA-11 PET/CT imaging findings in 77 black South-African (BSAs) and 18 white South-African (WSAs) treatment-naïve primary prostate carcinoma (PPC) patients. METHODS: (68)Ga-PSMA-11 PET/CT imaging findings were compared to histological, biochemical and morphological imaging data. Patients were grouped into three Gleason grade groups (GG), GG 1 (scores 3 + 3 and 3 + 4), GG2 (scores 4 + 3 and 4 + 4) and GG3 (scores 9 and 10), and the PSA difference among the groups was determined...
November 4, 2017: European Journal of Nuclear Medicine and Molecular Imaging
keyword
keyword
110902
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"